Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Retinal Vein Occlusion-Pipeline Review, H1 2015

Retinal Vein Occlusion-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Retinal Vein Occlusion-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Retinal Vein Occlusion-Pipeline Review, H1 2015', provides an overview of the Retinal Vein Occlusion's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Retinal Vein Occlusion Overview 8

Therapeutics Development 9

Pipeline Products for Retinal Vein Occlusion-Overview 9

Pipeline Products for Retinal Vein Occlusion-Comparative Analysis 10

Retinal Vein Occlusion-Therapeutics under Development by Companies 11

Retinal Vein Occlusion-Therapeutics under Investigation by Universities/Institutes 12

Retinal Vein Occlusion-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Retinal Vein Occlusion-Products under Development by Companies 16

Retinal Vein Occlusion-Products under Investigation by Universities/Institutes 17

Retinal Vein Occlusion-Companies Involved in Therapeutics Development 18

Aerpio Therapeutics, Inc. 18

Allergan, Inc. 19

Avalanche Biotechnologies, Inc. 20

F. Hoffmann-La Roche Ltd. 21

Kala Pharmaceuticals, Inc. 22

Mabion SA 23

NicOx S.A. 24

Ohr Pharmaceutical Inc. 25

pSivida Corp. 26

Regeneron Pharmaceuticals, Inc. 27

ThromboGenics NV 28

Retinal Vein Occlusion-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

aflibercept (recombinant)-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

AKB-9778-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AVA-101-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

beclomethasone dipropionate-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

fluocinolone acetonide-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

loteprednol etabonate-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

NCX-422-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

NCX-434-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

ocriplasmin (recombinant)-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Peptides to Inhibit Phosphatidylserine for Central Retinal Vein Occlusion-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ranibizumab-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ranibizumab biosimilar-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Recombinant Protein for Central Retinal Vein Occlusion-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

squalamine lactate-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Retinal Vein Occlusion-Recent Pipeline Updates 64

Retinal Vein Occlusion-Discontinued Products 95

Retinal Vein Occlusion-Product Development Milestones 96

Featured News & Press Releases 96

Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 96

Feb 26, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion 96

Dec 01, 2014: Bayer Receives Health Canada Approval For Eylea For Two Additional Indications 97

Sep 04, 2014: Regeneron Announces Submission of Application for EYLEA (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion 98

Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 98

Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 99

Jun 11, 2014: Bayer Submits Aflibercept Solution for Injection Into the Eye for Fourth Indication in EU 100

Nov 22, 2013: EYLEA Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan 100

Nov 12, 2013: Regeneron Highlights EYLEA (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting 101

Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 103

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H1 2015 9

Number of Products under Development for Retinal Vein Occlusion-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Retinal Vein Occlusion-Pipeline by Aerpio Therapeutics, Inc., H1 2015 18

Retinal Vein Occlusion-Pipeline by Allergan, Inc., H1 2015 19

Retinal Vein Occlusion-Pipeline by Avalanche Biotechnologies, Inc., H1 2015 20

Retinal Vein Occlusion-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 21

Retinal Vein Occlusion-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 22

Retinal Vein Occlusion-Pipeline by Mabion SA, H1 2015 23

Retinal Vein Occlusion-Pipeline by NicOx S.A., H1 2015 24

Retinal Vein Occlusion-Pipeline by Ohr Pharmaceutical Inc., H1 2015 25

Retinal Vein Occlusion-Pipeline by pSivida Corp., H1 2015 26

Retinal Vein Occlusion-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 27

Retinal Vein Occlusion-Pipeline by ThromboGenics NV, H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Retinal Vein Occlusion Therapeutics-Recent Pipeline Updates, H1 2015 64

Retinal Vein Occlusion-Discontinued Products, H1 2015 95

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H1 2015 9

Number of Products under Development for Retinal Vein Occlusion-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aerpio Therapeutics, Inc.

Allergan, Inc.

Avalanche Biotechnologies, Inc.

F. Hoffmann-La Roche Ltd.

Kala Pharmaceuticals, Inc.

Mabion SA

NicOx S.A.

Ohr Pharmaceutical Inc.

pSivida Corp.

Regeneron Pharmaceuticals, Inc.

ThromboGenics NV

Retinal Vein Occlusion Therapeutic Products under Development, Key Players in Retinal Vein Occlusion Therapeutics, Retinal Vein Occlusion Pipeline Overview, Retinal Vein Occlusion Pipeline, Retinal Vein Occlusion Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com